Mortality benefits seen with nirmatrelvir/ritonavir monotherapy
13 Dec 2025
Treatment with nirmatrelvir/ritonavir significantly reduced mortality risk among hospitalized COVID-19 patients compared with the combined molnupiravir and nirmatrelvir/ritonavir regimen, according to a target trial emulation study presented at IDWeek 2025.
Resources
Mortality benefits seen with nirmatrelvir/ritonavir monotherapy
Mortality benefits seen with nirmatrelvir/ritonavir monotherapy